---
title: Track disease progression in Parkinson
nct_id: NCT07353463
status: RECRUITING
sponsor: Ruijin Hospital
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07353463"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07353463"
last_fetched: "2026-05-10T14:05:33.416Z"
source: "Parkinson's Pathways (curated)"
---
# Track disease progression in Parkinson

**Goal (in five words):** Track disease progression in Parkinson

**Official Title:** Shanghai Clinical Cohort - Parkinson's Disease (Reserve)

**Trial ID:** [NCT07353463](https://clinicaltrials.gov/study/NCT07353463)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Ruijin Hospital
- **Target Enrollment:** 700 participants
- **Start Date:** 2025-04-01
- **Completion Date:** 2026-12-31
- **Conditions:** Parkinson's Disease (PD), Multiple System Atrophy

## Summary For Families

The goal is to build a large Shanghai cohort to find fluid and imaging biomarkers that help distinguish Parkinson's disease from multiple system atrophy and to track how each condition progresses. Participants give blood, saliva and optionally cerebrospinal fluid, and have MRI and PET/SPECT scans plus detailed motor and nonmotor assessments so researchers can link protein markers, genetics, and brain imaging patterns to symptoms and progression. The protocol is observational, so usual treatments like levodopa are not changed while data are collected. Eligible are adults diagnosed with PD by the Chinese 2016 criteria or clinically probable MSA by the 2022 consensus who can give informed consent and tolerate samples and imaging; people with unclear diagnoses, major brain lesions, severe psychiatric illness, serious organ failure, or inability to complete assessments are excluded.

## Eligibility

- **Sex:** ALL

### Full Criteria

```
* Inclusion Criteria for Clinical PD Group:

  1. Patients with a clinical diagnosis of Parkinson's disease (PD) according to the \_Chinese Diagnostic Criteria for Parkinson's Disease (2016 edition)\_.
  2. Willingness to undergo biospecimen collection, including cerebrospinal fluid (optional), blood, and saliva, and to complete neuroimaging examinations (MRI, PET/SPECT) and disease-specific clinical assessments.
  3. Provision of written informed consent
* Inclusion Criteria for Clinical MSA Group:

  1. Patients with a clinical diagnosis or clinically probable multiple system atrophy (MSA) according to the Chinese Expert Consensus on the Diagnostic Criteria for MSA (2022).
  2. Willingness to undergo biospecimen collection, including cerebrospinal fluid (optional), blood, and saliva, and to complete neuroimaging examinations (MRI, PET/SPECT) and disease-specific clinical assessments.
  3. Provision of written informed consent.
* Exclusion Criteria for All Participants:

  1. Patients with an unclear or uncertain diagnosis.
  2. History of stroke, head trauma, hydrocephalus, brain tumor, intracranial hypertension, or intracranial surgery.
  3. Evidence of intracranial organic lesions on CT/MRI.
  4. Severe anxiety, depression, or schizophrenia.
  5. Severe comorbidities involving the heart, lungs, liver, kidneys, endocrine system, or hematological system.
  6. Presence of aphasia, severe dysarthria, or other conditions that significantly impair clinical assessments.
  7. Anticipated poor compliance.
```

## Locations (1)

- Department of neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China _(31.2222, 121.4581)_
  - Jun Liu, Professor — (CONTACT) — +86-021-64370045 — lj11128@rjh.com.cn

## Central Contacts

- Jun Liu, Professor — (CONTACT) — +86-021-64370045 — lj11128@rjh.com.cn

---

*Canonical: https://parkinsonspathways.com/trial/NCT07353463*  
*HTML version: https://parkinsonspathways.com/trial/NCT07353463*  
*Source data: https://clinicaltrials.gov/study/NCT07353463*